Macular Degeneration Foundation believes a cap on the Medicare item number for the treatment of wet AMD should have minimal impact on patients.
Read MoreMacular Degeneration Foundation believes a cap on the Medicare item number for the treatment of wet AMD should have minimal impact on patients.
Read MoreThe TGA has approved a new drug, Eylea, for the treatment of wet (neovascular) age-related macular degeneration.
Read MoreABC to trial audio description on television to assist people who are blind or visually impaired.
Read MoreThe federal government has heard and acknowledged the Foundation’s postcard campaign for increased funding.
Read MoreThe 2011 Eyes on the Future report provides the most comprehensive compilation of macular degeneration statistics and research ever undertaken in Australia.
Read MoreThe Macular Degeneration Foundation is advocating for national subsidy scheme for low vision aids and technology for people with low vision.
Read MorePatients with wet macular degeneration (MD) who are receiving Avastin injections will again be entitled to a Medicare Rebate.
Read MoreAn advocacy campaign relating to the Extended Medicare Safety Net has been resolved positively for thousands of elderly Australians with wet AMD.
Read MoreMany macular degeneration clients are affected by the decision not to fund OCT.
Read More